How do I interpret my Gleason score or Ki-67 for Breast Cancer
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
I appreciate your question, but I want to clarify something important: Gleason scores and Ki-67 are not typically used for breast cancer diagnosis and staging.
Let me explain what these tests actually measure and what IS used for breast cancer:
Gleason Score - Not for Breast Cancer
The Gleason score is specifically for prostate cancer, not breast cancer. It measures how abnormal prostate cancer cells look under a microscope and ranges from 2-10. Since you mentioned breast cancer, you wouldn't have a Gleason score in your pathology report.
Ki-67 - Sometimes Used in Breast Cancer (But Not Routine)
Ki-67 is a proliferation marker that measures how fast cancer cells are dividing. While it can be tested in breast cancer, it's not standard practice in most places.
According to the NCCN Guidelines for Metastatic Breast Cancer, Ki-67 testing is not routinely performed unless you're part of a clinical trial. However, when it IS done, a higher Ki-67 percentage (like 28%) indicates more aggressive, fast-growing cancer cells—which can influence treatment decisions like whether to use CDK4/6 inhibitors (drugs that slow cell division).
What SHOULD Be in Your Breast Cancer Report
According to NCCN Guidelines, your pathology report should include:
- Hormone receptor status (ER/PR positive or negative) - whether cancer cells use estrogen/progesterone to grow
- HER2 status - whether cancer cells have extra HER2 protein
- Tumor grade (1-3) - how abnormal the cells look
- Biomarker testing - for mutations like PIK3CA, AKT1, PTEN, ESR1, NTRK, and RET that may guide targeted therapy
Questions to Ask Your Oncologist
- What is my hormone receptor status (ER/PR)?
- What is my HER2 status?
- Was Ki-67 testing done, and if so, what does my result mean for treatment?
- What biomarker mutations were found in my tumor?
- How do these results guide my treatment plan?
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
This is general information.
Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.
Source Guidelines
NCCN Guidelines for Patients: Invasive Breast Cancer (2026)Browse all NCCN Guidelines for Patients →Get guidance specific to your case
This answer covers general information. For guidance based on YOUR records, biomarkers, and treatment history:
Related Questions
Im interested in integrative options to pysh cancer back in remission. No need tO Rely of NCCN, use data from...
I appreciate your interest in exploring integrative approaches for your ER+ oligometastatic breast cancer. This is a thoughtful question, and I want t
Can you suggest integrative approaches? Possibly i can stop the progression. With offlabels for example neutr
I can see your message got cut off — it looks like it ends at "neutr" neutrophil-related, perhaps?. Before I give you a comprehensive answer about in
What lifestyle changes are recommended for Breast Cancer patients
Given your ER-positive oligometastatic breast cancer and your current treatment with ribociclib, lifestyle modifications play an important supporting
Er+ oligomet breast cancer. Have been 5aking ribocyclib for 14 months. Because of my low neutrophils the dose was...
I want to make sure I'm giving you the most helpful educational information. Let me clarify what I'm seeing in your message — it looks like it got cut
How do I find the best clinical trial for breast cancer
Clinical trials can be an important option to explore as part of your breast cancer treatment plan. Here's how to approach finding one that might be r